All Stories

Conduit taps Charles River to build preclinical autoimmune case for AstraZeneca diabetes asset

Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles River Laboratories to help test the asset in a preclinical model of the autoimmune disease.

Feb 13, 2025 - 21:19
 0
Conduit taps Charles River to build preclinical autoimmune case for AstraZeneca diabetes asset
Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles River Laboratories to help test the asset in a preclinical model of the autoimmune disease.
Read More

Tags:

Previous Article

IHG and Pacini Group Join Forces to Bring Garner Hotel Brand to Italy

Next Article

Own A Unique Piece Of Cinematic History: Yi Zhou’s New Artworks Include Archival...

Related Posts

Fierce Biotech Layoff Tracker 2025: Q32 Bio restructures; Viracta shuts down

Fierce Biotech Layoff Tracker 2025: Q32 Bio restructure...

Feb 10, 2025  0

Eli Lilly buys Organovo's FXR program for $10M, sending biotech's stock skyrocketing 244%

Eli Lilly buys Organovo's FXR program for $10M, sending...

Feb 26, 2025  0

Chutes & Ladders—NIH leaders join health agency exodus

Chutes & Ladders—NIH leaders join health agency exodus

Feb 21, 2025  0